New Haven drugmaker is Sen. Murphy's monthly innovator

Published on Monday, 12 August 2019 21:17
Written by Ciara Hooks


Kleo Pharmaceuticals, a New Haven-based immune-oncology company, was named Murphy’s Innovator of the Month on Aug. 7 by U.S. Sen. Chris Murphy.

Kleo was recognized for its advancement in the development of innovative bispecific compounds designed to emulate or enhance the activity of biologics to directly enlarge a patient’s immune system to target and destroy harmful cells.

“Kleo Pharmaceuticals is proof that Connecticut is a major hub for innovation. Their cutting-edge research and approach is being used to create products that will make a difference in the lives of people suffering from cancer. I’m happy to recognize Kleo as my ‘Innovator of the Month’ for their amazing work and commitment to Connecticut,” said Murphy.

Kleo will be advancing several drug candidates based on its proprietary technology platform and has partnered with Tokyo-based biopharmaceutical company PeptiDream to create a proprietary immune-oncology product to treat multiple myeloma.

“Kleo is pleased to accept Senator Murphy’s award, and we are committed to the New Haven community and to helping grow Connecticut’s biopharmaceutical sector,” said Dr. Douglas Mansion, the CEO of Kleo.

After four years, the 18-person company will expand to a new office space in New Haven and plans a 30 percent increase in staff.

“Our company has come a long way, and we are honored to be recognized for our accomplishments along with other emerging companies in Connecticut. In the last several months, we have worked diligently to redesign our office space and labs, remodel our website and push forward our development of next-generation immune-oncology drugs,” said Mansion.

Posted in New Britain Herald, Business, on Monday, 12 August 2019 21:17. Updated: Monday, 12 August 2019 21:20.